Roberta Maria Antonello
Overview
Explore the profile of Roberta Maria Antonello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Antonello R, Borchi B, Cavallo A, Mencarini J, Somma G, Bartoloni A, et al.
Respir Med Case Rep
. 2025 Jan;
52:102139.
PMID: 39764213
Cystic fibrosis (CF)-related central (CNS) and peripheral nervous system (PNS) disorders have not yet been fully described. We report the first case of post-infective neuromuscular hyperexcitability syndrome in a 23-year-old...
2.
Barbiero A, Spinicci M, Aiello A, Maruotto M, Antonello R, Formica G, et al.
Microorganisms
. 2024 Oct;
12(10).
PMID: 39458272
Human leishmaniasis is facing important epidemiological changes in Southern Europe, driven by increased urbanization, climate changes, emerging of new animal reservoirs, shifts in human behavior and a growing population of...
3.
Geremia N, Sanson G, Principe L, Antonello R, Zerbato V, Luzzati R, et al.
Anaerobe
. 2024 Aug;
90:102901.
PMID: 39214165
Clostridium perfingens bloodstream infections (BSIs) can be associated with high mortality rates. We performed a subanalysis of all C. perfringens BSIs enrolled during a multicentric retrospective observational study (ITANAEROBY). Data...
4.
Antonello R, Formica G, Attala L, Mannini D, Zammarchi L, Bartoloni A, et al.
IDCases
. 2024 Aug;
37:e02034.
PMID: 39135893
Toscana virus (TOSV) is an emerging cause of central nervous system (CNS) infections, especially in endemic countries during summer. Cerebrospinal fluid (CSF) is usually clear, with < 500 leukocytes/mm, normal...
5.
Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19
Antonello R, Marangoni D, Ducci F, Barbiero A, Manciulli T, Graziani L, et al.
J Chemother
. 2024 Jun;
37(2):130-134.
PMID: 38873733
The management of severe/prolonged SARS-CoV-2 infections in immunocompromised hosts is still challenging. We describe nine patients with hematologic malignancies with a history of unsuccessful SARS-CoV-2 treatment receiving antiviral combination treatment...
6.
Riccardi N, Antonello R, Ferrarese M, Repossi A, Saderi L, Fumagalli G, et al.
Monaldi Arch Chest Dis
. 2024 Jan;
PMID: 38213289
Tuberculosis (TB) diagnosis and management in special populations remain challenging. Data about TB and transgender individuals is scarce, and strategies aimed at reducing the TB burden in this at-risk group...
7.
Riccardi N, Occhineri S, Vanino E, Antonello R, Pontarelli A, Saluzzo F, et al.
Antibiotics (Basel)
. 2023 Dec;
12(12).
PMID: 38136767
Tuberculosis (TB) remains one of the leading causes of morbidity and mortality worldwide and pulmonary TB (PTB) is the main variant responsible for fueling transmission of the infection. Effective treatment...
8.
Antonello R, Riccardi N, Saderi L, Sotgiu G
Eur J Clin Microbiol Infect Dis
. 2023 Nov;
43(1):17-31.
PMID: 37975976
Purpose: Vancomycin-resistant enterococci (VRE) are a leading cause of hospital-acquired infections with limited therapeutic options. Combination of at least two antimicrobials is a possible strategy to obtain rapid and sustained...
9.
Riccardi N, Antonello R, Ferrarese M, Saderi L, Besozzi G, Sotgiu G, et al.
Infect Dis (Lond)
. 2023 May;
55(8):543-550.
PMID: 37255343
Background: Human migration and the ever-changing geopolitical scenarios are redefining the epidemiology and the management of tuberculosis (TB), especially in low-TB burden countries welcoming high rates of people from high-TB...
10.
Marangoni D, Antonello R, Coppi M, Palazzo M, Nassi L, Streva N, et al.
Int J Infect Dis
. 2023 May;
133:53-56.
PMID: 37150351
Immunocompromised patients still experience unpredictable courses of COVID-19, despite that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral combination regimens may have a role in SARS-CoV-2 infection in...